Clinical Profiles of Current and Emerging GLP-1 RAS

This CME-accredited CME Snapshot™ four-part series is intended for endocrinologists, primary care providers (PCPs), and other health care providers involved in the identification, evaluation, and treatment of patients with T2DM. During these activities, two expert faculty will participate in a series of interactive discussions on recent evidence related to glucagon-like peptide 1 receptor agonists (GLP-1 RAs). The faculty will also review freely available patient- and caregiver directed educational resources that seek to improve shared decision-making.

Target Audience

These activities have been designed to meet the educational needs of endocrinologists, PCPs (eg, internists, family physicians, nurse practitioners, and physician assistants), and other clinicians who manage patients with T2DM.

Educational Objectives 

Upon completion of these activities, participants should be better able to do the following:

  1. Discuss the latest published evidence for current and emerging GLP-1 receptor agonists as therapies for T2DM
  2. Tailor antihyperglycemic regimens for patients with T2DM using injectable noninsulin medications based on individualized goals, cardiovascular risks, and other clinical considerations

Faculty

 

John E. Anderson, MD
Internist
Past President, The Frist Clinic
Nashville, Tennessee

John (Jack) L. Leahy, MD
Professor of Medicine
The University of Vermont Larner College of Medicine
Director, Endocrinology
The University of Vermont Medical Center
Burlington, Vermont

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:

Name of Faculty or Presenter

Relationship Identified With:

John E. Anderson, MD

Consultant/Advisor: Abbott Diabetes Care, AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., sanofi-aventis U.S. LLC

Speakers’ Bureau: AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

John (Jack) L. Leahy, MD

Consultant/Advisor: Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., sanofi-aventis U.S. LLC, Valeritas, Inc.

Speakers’ Bureau: Merck & Co., Inc.

Non-faculty: Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Novo Nordisk Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications. 

 

CME Credit (Physicians)

These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician
Course opens: 
08/07/2018
Course expires: 
08/06/2019
Rating: 
0

Available Credit

  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician

Accreditation Period

Course opens: 
08/07/2018
Course expires: 
08/06/2019
Please login or register to take this course.